SEC Form 4 · accession 0001104659-16-139406
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Kenneth Charles Knowles
Director
Period of report
Aug 11, 2016
Accepted (ET)
Aug 12, 2016 · 6:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1 | $1.27 | Aug 11, 2016 | A | 217,222 | A | Aug 11, 2017 | Aug 11, 2026 | Ordinary Shares | 217,222 | 217,222 | D |
Explanation of responses
- F1The exercise price was converted from GBP0.97 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.